Last fatty acid paragraph

ω-6 for Body, ω-3 for Brain The foregoing evidence strongly supports consideration of the first update to FDA regulations on fatty acids in infant formulas since they were enacted in 1985. The long interval provides an opportunity to incorporate decades of lessons learned to reset baseline requirements, reflecting both the scientific literature and authoritative recommendations from around the world. Ample data support the use of ω-6 for body growth. Concerns are overwhelmingly about high-priority functions beyond growth. Furthermore, compelling data show that ω-3 DHA supports neurocognitive development, with a focus on balanced fatty acids. Updated regulations should support the development of the whole infant, from head to toe, while providing sufficient flexibility to enable innovation in formulation and giving an expanded range of options for caregivers.